No Data
BioLineRx Shares Are Trading Higher After the Company Announces That the First Patient Has Been Dosed in Its Phase 1/2A Study of GLIX-1 for Glioblastoma and Other High-grade Gliomas.
BioLineRx Announces That The First Patient Has Been Dosed In Its Phase 1/2A Study Of GLIX-1 For The Treatment Of Recurrent And Progressive Glioblastoma And Other High-Grade Gliomas
JonesTrading Maintains BioLine Rx(BLRX.US) With Buy Rating, Maintains Target Price $12
BioLineRx: Advancing GLIX1 and Motixafortide Pipeline With Strengthened IP and Legal Position Underpinning Buy Rating and $12 Target
BioLine Rx | 20-F/A: Registration statement / Annual report / Transition report (Amendment)
BioLineRx Launches First-in-Human Trial of GLIX1 for Glioblastoma